A multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric cancer

Basit Öğe Kaydı
dc.contributor.authorKurt, E.
dc.contributor.authorCubukcu, E.
dc.contributor.authorKarabulut, B.
dc.contributor.authorOlmez, O. F.
dc.contributor.authorKurt, M.
dc.contributor.authorAvci, N.
dc.contributor.authorOzdemir, F.
dc.contributor.authorTunali, D.
dc.contributor.authorEvrensel, T.
dc.contributor.authorManavoglu, O.
dc.date.accessioned2019-10-27T21:54:10Z
dc.date.available2019-10-27T21:54:10Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose: Albeit the majority of gastric cancers occur at advanced age, little is known regarding the optimal systemic treatment of elderly patients with advanced gastric cancer (AGC). Methods: Patients with AGC who were >= 65 years old and were treated with carboplatin (area under the curve/AUG 5, on day 1, every 3 weeks) plus docetaxel (75 mg/m(2), on day 1, every 3 weeks) at 3 institutions were included in this retrospective analysis. The efficacy and the safety data of the regimen were analyzed. Results: A total of 30 patients were enrolled. They received 128 cycles of chemotherapy, with a median of 4 cycles (range 2-8). Complete response (CR) and partial response (PR) were observed in 2 (6.7%) and 10 patients (33.3%), respectively, amounting to an overall objective response rate (ORR) of 40%. Seven patients (23.3%) had disease stabilization (SD), and 11(36.7%) showed disease progression (PD). The most common grade 3-4 toxicity was neutropenia occurring in 19 patients (63.3%). The mean progression-free survival (PFS) was 6.0 +/- 0.5 months (95% CI: 5.0-7.4), and the mean overall survival (OS) 12.0 +/- 1.0 months (95% CI: 9.2-12.1). Conclusion: Carboplatin plus docetaxel seems to be an active and well-tolerated regimen, representing a valuable alternative to cisplatin- and/or fluoropyrimidine-containing regimens for the treatment of elderly patients with AGC.en_US
dc.identifier.endpage153en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1en_US
dc.identifier.pmid23613400en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage147en_US
dc.identifier.urihttps://hdl.handle.net/11454/48035
dc.identifier.volume18en_US
dc.identifier.wosWOS:000322750600018en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcarboplatinen_US
dc.subjectdocetaxelen_US
dc.subjectelderlyen_US
dc.subjectgastric canceren_US
dc.titleA multi-institutional evaluation of carboplatin plus docetaxel combination in elderly patients with advanced gastric canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu